Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects-Reference-Cited by-同舟云学术

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects

Published:2006-02 Issue:2 Volume:17 Page:232-238
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Colleoni M.,Orlando L.,Sanna G.,Rocca A.,Maisonneuve P.,Peruzzotti G.,Ghisini R.,Sandri M.T.,Zorzino L.,Nolè F.,Viale G.,Goldhirsch A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/2/232/392443/mdj066.pdf

Reference30 articles.

1. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice;Hanahan;J Clin Invest,2000

2. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer;Browder;Cancer Res,2000

3. High-time chemotherapy or high time for low dose;Kamen;J Clin Oncol,2000

4. Antiangiogenic scheduling of lower dose cancer chemotherapy;Gately;Cancer J,2001

5. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels;Colleoni;Ann Oncol,2002

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial;Journal of Chemotherapy;2024-05-20

2. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology;Heliyon;2024-02

3. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer;Breast Cancer Research and Treatment;2023-11-29

4. Metronomic Chemotherapy;Therapeutic Strategies in Veterinary Oncology;2023-08-23

5. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma;Digestive and Liver Disease;2023-08